מנבאו

Country: Israel

Language: Hebrew

Source: Ministry of Health

Active ingredient:

MENINGOCOCCAL VACCINES GROUP A; MENINGOCOCCAL VACCINES GROUP C; MENINGOCOCCAL VACCINES GROUP W; MENINGOCOCCAL VACCINES GROUP Y

Available from:

GLAXO SMITH KLINE (ISRAEL) LTD

ATC code:

J07AH02

Pharmaceutical form:

POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

Composition:

MENINGOCOCCAL VACCINES GROUP Y 5 MCG / 0.5 ML; MENINGOCOCCAL VACCINES GROUP W 5 MCG / 0.5 ML; MENINGOCOCCAL VACCINES GROUP C 5 MCG / 0.5 ML; MENINGOCOCCAL VACCINES GROUP A 10 MCG / 0.5 ML

Administration route:

תוך-שרירי

Prescription type:

מרשם נדרש

Manufactured by:

GLAXO SMITHKLINE VACCINES S.R.L., ITALY

Therapeutic group:

OTHER MENINGOCOCCAL MONOVALENT PURIFIED POLYSACCHARIDES ANTIGEN

Therapeutic area:

OTHER MENINGOCOCCAL MONOVALENT PURIFIED POLYSACCHARIDES ANTIGEN

Therapeutic indications:

Menveo is indicated for active immunization of children (2 years of age and above), adolescents and adults up to the age of 55 years, at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease. The use of this vaccine should be in accordance with official recommendations.

Product summary:

החיסון יינתן עבור חולה הלוקה באחד מאלה:1. אספלניה, היפוספלניה אנטומית או תפקודית, נרכשת או מולדת.2. חסר במערכת המשלים כגון חסר בפקטור D, פרופרידין ובמרכיב המשלים C5-9 או C3

Authorization date:

2017-08-31